Challenges of Implementing Innovation in Drug Discovery and Development
Date: Tuesday, September 15, 2020
Time: 9:00am PDT / 12:00pm EDT
Duration: 1 hour
The measurement of multiple biological activities following drug treatment of cell-based systems, a central tenant of phenotypic screening and profiling, is experiencing a renaissance in drug discovery as companies look beyond
biochemical approaches to complex cell and tissue systems with high physiological relevance. Previously, challenges of
data interpretation and limited data analytics, unclear relevance or benefit to human disease, and lack of throughput
and leadership support for this approach hindered broad adoption. Many of these issues now have robust data-rich
solutions, and leading scientists are reaping the benefits of an activity profiling approach. This thought leadership
webinar brings together unique perspectives – from start-up to mid-size biotech and large global pharma – through
discussion of challenges and achievements in implementing biomarker activity profiling strategies for pipeline
progression. With audience Q&A, panelists will shed light on obvious, and less obvious, aspects of determining when a
phenotypic approach can be beneficial, and how to integrate or supplement this innovation into a drug discovery and
development strategy. Join Eurofins Discovery Phenotypic Center of Excellence for some serious fun.
Alison O’Mahony, Ph.D.
Vice President, Translational Biology
Lisa Schopf, Ph.D.
Stephanie Venn-Watson, DVM, MPH
Co-Founder, Chief Executive Officer
Kieron Edwards, MBA, Ph.D.
Chief Scientific Officer